Publications

PUBLICATIONS

Occleston NL, O'Kane S, Laverty HG, Cooper M, Fairlamb D, Mason T, Bush JA, Ferguson MW. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48. doi: 10.1111/j.1524-475X.2011.00711.x. PMID: 21793965.

Bush J, So K, Mason T, Occleston NL, O'Kane S, Ferguson MW. Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring. Dermatol Res Pract. 2010;2010:690613. doi: 10.1155/2010/690613. Epub 2010 Aug 3. PMID: 20811604; PMCID: PMC2929517.

Occleston NL, Metcalfe AD, Boanas A, Burgoyne NJ, Nield K, O'Kane S, Ferguson MW. Therapeutic improvement of scarring: mechanisms of scarless and scar-forming healing and approaches to the discovery of new treatments. Dermatol Res Pract. 2010;2010:405262. doi: 10.1155/2010/405262. Epub 2010 Aug 3. PMID: 20811598; PMCID: PMC2929503.

Laverty HG, Occleston NL, Johnson M, Little J, Jones R, Fairlamb D, Ferguson MW, O'Kane S. Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds. J Cutan Med Surg. 2010 Sep-Oct;14(5):223-32. doi: 10.2310/7750.2010.09069. PMID: 20868619.

Occleston NL, Fairlamb D, Hutchison J, O'Kane S, Ferguson MW. Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area. Expert Opin Investig Drugs. 2009 Aug;18(8):1231-9. doi: 10.1517/13543780903130594. PMID: 19604123.

Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet. 2009 Apr 11;373(9671):1264-74. doi: 10.1016/S0140-6736(09)60322-6. PMID: 19362676.

Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW. TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev. 2009 Aug;20(4):305-17. doi: 10.1016/j.cytogfr.2009.07.002. Epub 2009 Aug 4. PMID: 19656717; PMCID: PMC7294566.

Occleston NL, Laverty HG, O'Kane S, Ferguson MW. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical. J Biomater Sci Polym Ed. 2008;19(8):1047-63. doi: 10.1163/156856208784909345. PMID: 18644230.

Occleston NL, O'Kane S, Goldspink N, Ferguson MW. New therapeutics for the prevention and reduction of scarring. Drug Discov Today. 2008 Nov;13(21-22):973-81. doi: 10.1016/j.drudis.2008.08.009. Epub 2008 Oct 15. PMID: 18824245.

Durani P, Occleston N, O'Kane S, Ferguson MW. Avotermin: a novel antiscarring agent. Int J Low Extrem Wounds. 2008 Sep;7(3):160-8. doi: 10.1177/1534734608322983. PMID: 18757391.

Atkins S, Loescher AR, Boissonade FM, Smith KG, Occleston N, O'Kane S, Ferguson MW, Robinson PP. Interleukin-10 reduces scarring and enhances regeneration at a site of sciatic nerve repair. J Peripher Nerv Syst. 2007 Dec;12(4):269-76. doi: 10.1111/j.1529-8027.2007.00148.x. PMID: 18042137.

Constable PH, Crowston JG, Occleston NL, Khaw PT. The effects of single doses of beta radiation on the wound healing behaviour of human Tenon's capsule fibroblasts. Br J Ophthalmol. 2004 Feb;88(2):169-73. doi: 10.1136/bjo.2003.020388. PMID: 14736764; PMCID: PMC1772003.

Fray MJ, Dickinson RP, Huggins JP, Occleston NL. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. doi: 10.1021/jm0308038. PMID: 12877590.

Daniels JT, Cambrey AD, Occleston NL, Garrett Q, Tarnuzzer RW, Schultz GS, Khaw PT. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1104-10. doi: 10.1167/iovs.02-0412. PMID: 12601036.

Sheridan CM, Occleston NL, Hiscott P, Kon CH, Khaw PT, Grierson I. Matrix metalloproteinases: a role in the contraction of vitreo-retinal scar tissue. Am J Pathol. 2001 Oct;159(4):1555-66. doi: 10.1016/S0002-9440(10)62540-0. PMID: 11583981; PMCID: PMC1850496.

Stephens P, Davies KJ, Occleston N, Pleass RD, Kon C, Daniels J, Khaw PT, Thomas DW. Skin and oral fibroblasts exhibit phenotypic differences in extracellular matrix reorganization and matrix metalloproteinase activity. Br J Dermatol. 2001 Feb;144(2):229-37. doi: 10.1046/j.1365-2133.2001.04006.x. PMID: 11251552.

Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000 May;84(5):506-11. doi: 10.1136/bjo.84.5.506. PMID: 10781515; PMCID: PMC1723478.

Wilkins MR, Occleston NL, Kotecha A, Waters L, Khaw PT. Sponge delivery variables and tissue levels of 5-fluorouracil. Br J Ophthalmol. 2000 Jan;84(1):92-7. doi: 10.1136/bjo.84.1.92. PMID: 10611106; PMCID: PMC1723231.

Daniels JT, Occleston NL, Crowston JG, Khaw PT. Effects of antimetabolite induced cellular growth arrest on fibroblast-fibroblast interactions. Exp Eye Res. 1999 Jul;69(1):117-27. doi: 10.1006/exer.1999.0684. PMID: 10375456.

Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):705-12. PMID: 10067974.

Constable PH, Crowston JG, Occleston NL, Cordeiro MF, Khaw PT. Long term growth arrest of human Tenon's fibroblasts following single applications of beta radiation. Br J Ophthalmol. 1998 Apr;82(4):448-52. doi: 10.1136/bjo.82.4.448. PMID: 9640199; PMCID: PMC1722552.

Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1524-9. PMID: 9660504.

Porter RA, Brown RA, Eastwood M, Occleston NL, Khaw PT. Ultrastructural changes during contraction of collagen lattices by ocular fibroblasts. Wound Repair Regen. 1998 Mar-Apr;6(2):157-66. doi: 10.1046/j.1524-475x.1998.60210.x. PMID: 9776859.

Khan U, Occleston NL, Khaw PT, McGrouther DA. Differences in proliferative rate and collagen lattice contraction between endotenon and synovial fibroblasts. J Hand Surg Am. 1998 Mar;23(2):266-73. doi: 10.1016/S0363-5023(98)80125-1. PMID: 9556267.

Daniels JT, Occleston NL, Crowston JG, Cordeiro MF, Alexander RA, Wilkins M, Porter R, Brown R, Khaw PT. Understanding and controlling the scarring response: the contribution of histology and microscopy. Microsc Res Tech. 1998 Sep 1;42(5):317-33. doi: 10.1002/(SICI)1097-0029(19980901)42:5<317::AID- JEMT3>3.0.CO;2-M. PMID: 9766427.

Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998 Feb;39(2):449-54. PMID: 9478007.

Kon CH, Occleston NL, Foss A, Sheridan C, Aylward GW, Khaw PT. Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 1998 May;82(5):554-60. doi: 10.1136/bjo.82.5.554. PMID: 9713065; PMCID: PMC1722588.

Occleston NL, Daniels JT, Tarnuzzer RW, Sethi KK, Alexander RA, Bhattacharya SS, Schultz GS, Khaw PT. Single exposures to antiproliferatives: long-term effects on ocular fibroblast wound-healing behavior. Invest Ophthalmol Vis Sci. 1997 Sep;38(10):1998-2007. PMID: 9331263.

Cordeiro MF, Occleston NL, Khaw PT. New concepts: manipulation of the wound- healing response. Dev Ophthalmol. 1997;28:242-60. doi: 10.1159/000060701. PMID: 9386947.

Khan U, Occleston NL, Khaw PT, McGrouther DA. Single exposures to 5-fluorouracil: a possible mode of targeted therapy to reduce contractile scarring in the injured tendon. Plast Reconstr Surg. 1997 Feb;99(2):465-71. doi: 10.1097/00006534-199702000-00023. PMID: 9030156.

Foss AJ, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription- polymerase chain reaction. Br J Cancer. 1995 Jul;72(1):155-9. doi: 10.1038/bjc.1995.293. PMID: 7599046; PMCID: PMC2034111.

Occleston NL, Alexander RA, Mazure A, Larkin G, Khaw PT. Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction. Invest Ophthalmol Vis Sci. 1994 Sep;35(10):3681-90. PMID: 8088956.

Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye (Lond). 1994;8 ( Pt 2):188-95. doi: 10.1038/eye.1994.44. PMID: 7958020.

Pendleton N, Occleston NL, Walshaw MJ, Littler JA, Jack CI, Myskow MW, Green JA. Simple cytokeratins in the serum of patients with lung cancer: relationship to cell death. Eur J Cancer. 1994;30A(1):93-6. doi: 10.1016/s0959-8049(05)80026-7. PMID: 7511403.

Occleston NL, Walker C. Production of multiple growth factors by a human non-small cell lung carcinoma cell line. Cancer Lett. 1993 Jul 30;71(1-3):203-10. doi: 10.1016/0304-3835(93)90117-r. PMID: 8395975.

Pendleton N, Dixon GR, Burnett HE, Occleston NL, Myskow MW, Green JA. Expression of proliferating cell nuclear antigen (PCNA) in dysplasia of the bronchial epithelium. J Pathol. 1993 Jun;170(2):169-72. doi: 10.1002/path.1711700212. PMID: 8102179.

Get In Touch

Occleston Biopharma

Scientific and Project Management Consultancy Services

PUBLICATIONS

Occleston Biopharma

Scientific and Project Management Consultancy Services

PUBLICATIONS

This website uses cookies.